Episode Details

Elanco Animal Health (ELAN) Q2 2026 — Q2 2026 (quarter ended June 30, 2026): revenue $1,368M +10% (+8% organic constant currency), adjusted EPS $0.34 +31% vs a $0.27 bar, GAAP EPS $0.11, adjusted EBITDA $288M +21% at a 21.2% margin. FY2026 guidance RAISED for the third straight quarter to $5.09-5.14B revenue and $1.10-$1.16 adjusted EPS. The 8-K was accepted 6:27 a.m. ET on Aug 5 (before the open), so the reaction is in the tape: ELAN opened at $27.08, ran to $27.98 intraday, closed $26.22, then fell 7.7% to $24.20 on Aug 6 and closed Aug 7 at $23.255 - minus 16.9% from the print-day high. Elanco beat the adjusted EPS bar by 26% ($0.34 vs $0.27), raised full-year guidance for the third straight quarter, and cut its year-end net leverage target - and the stock is down 16.9% from its print-day high. We tested the obvious cynical explanation first and it is FALSE: this was not a beat against a cut bar. Elanco RAISED its own guide in May to $0.25-$0.28 and then cleared the top of that raised range by 21%. The problem is somewhere else, and it is in the cash flow statement. In 2025 Elanco reported $901M of adjusted EBITDA; operating cash flow was $560M and capex $276M, so free cash flow was $284M - 31 cents on the adjusted EBITDA dollar. H1 2026 converted at 33% ($622M adjusted EBITDA, $290M operating cash flow, $84M net capex, $206M free cash flow), with working capital consuming $239M in six months. Second, the celebrated deleveraging is a denominator story: net leverage went 3.6x to 3.1x, but hold EBITDA still and the debt reduction alone gives 3.51x while holding debt still and applying EBITDA growth gives 3.22x - 76% of the improvement was the denominator, and the 10-Q shows only $89M of long-term borrowings repaid against $3,944M of gross debt. Third, Elanco's own definition of innovation revenue says it 'does not include the expected impact of cannibalization on the base portfolio': innovation goes $892M to a $1.25B target (+$358M) while total organic growth is guided at 6-7% (about +$307M), so the non-innovation base is shrinking roughly $51M, or 1.3%. And 79% of adjusted EPS ($0.27 of $0.34) is amortisation add-back against R&D that was FLAT at $92M. THE CALL: HOLD (3/5, A REAL BEAT, AND THE SELLOFF WAS STILL RIGHT) — base-case value ~$22.5 vs ~$23.255 today. KEY METRICS: - CALL: HOLD 3/5, fair value ~$22.50 vs the $23.255 Aug 7 close (-3.2%). Bull $28.75, base $20.30, bear $14.00. Street: Buy, 21 analysts, avg target $28.67. - Revenue $1,368M +10%. Adjusted EPS $0.34 vs a $0.27 bar (+26%). GAAP EPS $0.11. Adjusted EBITDA $288M +21%. FY26 guide RAISED a third time to $1.10-1.16. - But: FY2025 adjusted EBITDA $901M became $284M of free cash flow (31%). Deleveraging was 76% denominator - only $89M of debt repaid. Base shrinking 1.3%. What to watch: UP: working capital actually releasing in Q3 or Q4 with free cash flow conversion clearing 50%; the non-innovation base stabilising instead of shrinking; net leverage under 3.0x before year end; Elanco Ascend savings showing up early in the margin. DOWN: a third straight half of working-capital drag; innovation revenue hitting its target while total organic growth misses; R&D staying flat at $92M a quarter against $139M of quarterly amortisation; a 2027 guide that leans on price rather than volume. Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.